CA3228766A1 - Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer - Google Patents

Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer Download PDF

Info

Publication number
CA3228766A1
CA3228766A1 CA3228766A CA3228766A CA3228766A1 CA 3228766 A1 CA3228766 A1 CA 3228766A1 CA 3228766 A CA3228766 A CA 3228766A CA 3228766 A CA3228766 A CA 3228766A CA 3228766 A1 CA3228766 A1 CA 3228766A1
Authority
CA
Canada
Prior art keywords
pyridin
group
trifluoromethyl
c3alkyl
methylmorpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228766A
Other languages
English (en)
French (fr)
Inventor
Yasmin YU
Martin Andersson
Daniel L. Flynn
Madhumita BOGDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of CA3228766A1 publication Critical patent/CA3228766A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3228766A 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer Pending CA3228766A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232983P 2021-08-13 2021-08-13
US63/232,983 2021-08-13
US202263317500P 2022-03-07 2022-03-07
US63/317,500 2022-03-07
PCT/US2022/074925 WO2023019259A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3228766A1 true CA3228766A1 (en) 2023-02-16

Family

ID=83188606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228766A Pending CA3228766A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Country Status (7)

Country Link
US (1) US20250127790A1 (https=)
EP (1) EP4384180A1 (https=)
JP (1) JP2024532780A (https=)
AU (1) AU2022326573A1 (https=)
CA (1) CA3228766A1 (https=)
TW (1) TW202320797A (https=)
WO (1) WO2023019259A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
WO2019038387A1 (en) * 2017-08-23 2019-02-28 Sprint Bioscience Ab PYRIDYLPYRIDONE COMPOUNDS
CN111094271B (zh) * 2017-08-23 2023-02-28 思普瑞特生物科学公司 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Also Published As

Publication number Publication date
JP2024532780A (ja) 2024-09-10
TW202320797A (zh) 2023-06-01
WO2023019259A1 (en) 2023-02-16
EP4384180A1 (en) 2024-06-19
US20250127790A1 (en) 2025-04-24
AU2022326573A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
JP7678763B2 (ja) ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
JP6899975B2 (ja) Ｍｃｌ−１阻害剤
JP7626722B2 (ja) アミノピリミジンアミドオートファジー阻害剤およびその使用方法
US11014881B2 (en) Hepatitis B capsid assembly modulators
AU2002346053B2 (en) Tyrosine kinase inhibitors
US10030034B2 (en) Heterocycle amines and uses thereof
US6911440B2 (en) Phthalazine derivatives for treating inflammatory diseases
RS65019B1 (sr) Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
CN102480966B (zh) 融合的杂环化合物及其用途
JP4873352B2 (ja) Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
JP2023508054A (ja) Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
US11230545B2 (en) Heterocyclic compound
HU227972B1 (en) Phthalazines with angiogenesis inhibiting activity and pharmaceutical compositions containing them
JP2008530216A (ja) Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
TW201429957A (zh) 用於激酶調節及其適應症之化合物及方法
US20120142732A1 (en) Heteroaryls and uses thereof
KR20170033435A (ko) 단백질 키나제 c 억제제 및 그의 사용 방법
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
CA2888485A1 (en) Phenyl linked quinolinyl modulators of ror.gamma.t
CN108707139A (zh) 氨基嘧啶类化合物及其制备方法和应用
JP2020531528A (ja) イミダゾリジン化合物
TW201710250A (zh) 經取代之喹喏啉衍生物
CA3228766A1 (en) Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808